Therapeutic effect of thalidomide plus irinotecan and cisplatin for recurrent small cell lung cancer

VernacularTitle:伊立替康和顺铂联合沙利度胺治疗复发性小细胞肺癌疗效研究
Author: Junye WANG ; Dongyu HU
Publication Type:Journal Article
Keywords: Lung neoplasms; Neoplasm recurrence; Drug therapy,combination
From: Journal of International Oncology 2013;(4):306-308
CountryChina
Language:Chinese
Abstract: Objective To investigate the efficacy and toxicity of thalidomide plus irinotecan and cisplatin treatment for recurrent small cell lung cancer.Methods 62 Patients with recurrent small cell lung cancer in the same period were randomly divided into observation group and control group according to the principle of minimum distribution imbalance index.The observation group patients were treated with thalidomide plus irinotecan and cisplatin chemotherapy,and the control group patients were treated with irinotecan and cisplatin chemotherapy.The efficacy and toxicity of the two groups were compared.Results The overall response rate in the group observation was 86.7％ compared with 63.3％ in the control group,and the difference had statistical significance (x2 =8.52,P ＜ 0.05).The major toxicities were hematologic toxicity and gastrointestinal symptoms,and the side effects differences were not statistically significant (x2 =0.18,P ＞ 0.05).Conclusion The treatment of recurrent small cell lung cancer with irinotecan and cisplatin in combination with thalidomide has high efficiency,and the toxicity can be tolerated.